Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles

Shared on01 May 25

Shared on24 Apr 25
Fair value Increased 63%

Shared on17 Apr 25
Fair value Decreased 2.54%

AnalystConsensusTarget has increased revenue growth from -0.7% to -0.4% and decreased profit margin from 19.3% to 17.3%.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.